Hyloris Pharmaceuticals Reports Full Year 2023 Earnings

Hyloris Pharmaceuticals (EBR:HYL) Full Year 2023 Results

Key Financial Results

• Net loss: €15.8m (loss widened by 34% from FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hyloris Pharmaceuticals Earnings Insights

In the last 12 months, the only revenue segment was Pharmaceuticals contributing €2.81m. The largest operating expense was Research & Development (R&D) costs, amounting to €14.7m (78% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of €327.0k. Explore how HYL's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Belgium.

The company's shares are down 8.2% from a week ago.

Risk Analysis

We should say that we've discovered 3 warning signs for Hyloris Pharmaceuticals that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.